Compounds > pralnacasan
Page last updated: 2024-09-04

pralnacasan and paromomycin

pralnacasan has been researched along with paromomycin in 2 studies

Compound Research Comparison

Studies
(pralnacasan)		Trials
(pralnacasan)		Recent Studies (post-2010)
(pralnacasan)		Studies
(paromomycin)		Trials
(paromomycin)		Recent Studies (post-2010) (paromomycin)
19071,42290292

Protein Interaction Comparison

ProteinTaxonomypralnacasan (IC50)paromomycin (IC50)
30S ribosomal protein S6Escherichia coli K-120.0355
30S ribosomal protein S7Escherichia coli K-120.0355
50S ribosomal protein L15Escherichia coli K-120.0355
50S ribosomal protein L10Escherichia coli K-120.0355
50S ribosomal protein L11Escherichia coli K-120.0355
50S ribosomal protein L7/L12Escherichia coli K-120.0355
50S ribosomal protein L19Escherichia coli K-120.0355
50S ribosomal protein L1Escherichia coli K-120.0355
50S ribosomal protein L20Escherichia coli K-120.0355
50S ribosomal protein L27Escherichia coli K-120.0355
50S ribosomal protein L28Escherichia coli K-120.0355
50S ribosomal protein L29Escherichia coli K-120.0355
50S ribosomal protein L31Escherichia coli K-120.0355
50S ribosomal protein L31 type BEscherichia coli K-120.0355
50S ribosomal protein L32Escherichia coli K-120.0355
50S ribosomal protein L33Escherichia coli K-120.0355
50S ribosomal protein L34Escherichia coli K-120.0355
50S ribosomal protein L35Escherichia coli K-120.0355
50S ribosomal protein L36Escherichia coli K-120.0355
30S ribosomal protein S10Escherichia coli K-120.0355
30S ribosomal protein S11Escherichia coli K-120.0355
30S ribosomal protein S12Escherichia coli K-120.0355
30S ribosomal protein S13Escherichia coli K-120.0355
30S ribosomal protein S16Escherichia coli K-120.0355
30S ribosomal protein S18Escherichia coli K-120.0355
30S ribosomal protein S19Escherichia coli K-120.0355
30S ribosomal protein S20Escherichia coli K-120.0355
30S ribosomal protein S2Escherichia coli K-120.0355
30S ribosomal protein S3Escherichia coli K-120.0355
30S ribosomal protein S4Escherichia coli K-120.0355
30S ribosomal protein S5Escherichia coli K-120.0355
30S ribosomal protein S8Escherichia coli K-120.0355
30S ribosomal protein S9Escherichia coli K-120.0355
50S ribosomal protein L13Escherichia coli K-120.0355
50S ribosomal protein L14Escherichia coli K-120.0355
50S ribosomal protein L16Escherichia coli K-120.0355
50S ribosomal protein L23Escherichia coli K-120.0355
30S ribosomal protein S15Escherichia coli K-120.0355
50S ribosomal protein L17Escherichia coli K-120.0355
50S ribosomal protein L21Escherichia coli K-120.0355
50S ribosomal protein L30Escherichia coli K-120.0355
50S ribosomal protein L6Escherichia coli K-120.0355
30S ribosomal protein S14Escherichia coli K-120.0355
30S ribosomal protein S17Escherichia coli K-120.0355
30S ribosomal protein S1Escherichia coli K-120.0355
50S ribosomal protein L18Escherichia coli K-120.0355
50S ribosomal protein L2Escherichia coli K-120.0355
50S ribosomal protein L3Escherichia coli K-120.0355
50S ribosomal protein L24Escherichia coli K-120.0355
50S ribosomal protein L4Escherichia coli K-120.0355
50S ribosomal protein L22Escherichia coli K-120.0355
50S ribosomal protein L5Escherichia coli K-120.0355
30S ribosomal protein S21Escherichia coli K-120.0355
50S ribosomal protein L25Escherichia coli K-120.0355
50S ribosomal protein L36 2Escherichia coli K-120.0355

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for pralnacasan and paromomycin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for pralnacasan and paromomycin

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011